Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

  • This first-to-market launch showcases Teva’s proven strengths in complex generic formulations and enhances Teva’s strategic goal of sustaining a generic powerhouse.
  • Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sandostatin®1 LAR Depot, in the United States.

Octreotide acetate for injectable suspension (the generic version of Sandostatin® LAR Depot) is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome. Please see the below for more information.

“With today’s launch of octreotide acetate for injectable suspension (the generic version of Sandostatin® LAR Depot), Teva is providing patients a new option for this important treatment,” said Ernie Richardsen, SVP U.S. Commercial Generics.” He continued, “This first-to-market launch showcases Teva’s expertise in bringing complex generic formulations to market and demonstrates once again our ability to not only sustain a generics powerhouse, but also to bring value to patients and healthcare systems.”

Sandostatin® LAR Depot had annual sales of $826 million as of July 2024, according to IQVIA data.

What is octreotide acetate for injectable suspension (the generic version of Sandostatin® LAR Depot)?
Octreotide acetate for injectable suspension (the generic version of Sandostatin® LAR Depot) is a prescription medication used in patients in whom initial treatment with octreotide acetate injection has been shown to be effective and tolerated for:

  • Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy, is not an option to reduce GH and IGF-1 levels to normal.
  • Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
  • Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors.

In patients with carcinoid tumors and VIP-secreting tumors, the effect of octreotide acetate injection and octreotide acetate for injectable suspension on tumor size, rate of growth and development of metastases, has not been determined.

IMPORTANT SAFETY INFORMATION
What is the most important information I should know about octreotide acetate for injectable suspension (the generic version of Sandostatin® LAR Depot)? 
Treatment with octreotide acetate for injectable suspension (the generic version of Sandostatin® LAR Depot) may affect gallbladder function, with reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Tell your doctor if you experience signs or symptoms of gallstones or any of their complications.
Patients with carcinoid tumors and VIP-secreting tumors should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.
Patients with acromegaly should adhere to their return visit schedule to help assure steady control of GH and IGF-1 levels.
What should I tell my doctor before taking octreotide acetate for injectable suspension (the generic version of Sandostatin® LAR Depot)? 
Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.
What are the possible side effects of octreotide acetate for injectable suspension (the generic version of Sandostatin® LAR Depot)? 
In acromegalic patients, the most common side effects of octreotide acetate for injectable suspension include gallstones, diarrhea, abdominal pain, gas, flu-like symptoms, constipation, headache, low red blood cells, injection-site pain, gallstones, high blood pressure, dizziness and fatigue.
In carcinoid tumor and VIP-secreting tumor patients, the most common side effects of octreotide acetate for injectable suspension include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.
These are not all of the possible side effects of octreotide acetate for injectable suspension. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the full Prescribing Information.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: the launch and commercial success of octreotide acetate for injectable suspension (the generic version of Sandostatin® LAR Depot); our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; delays in launches of new generic products; our ability to develop and commercialize biopharmaceutical products; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to sustain and focus our portfolio of generics medicines; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. 

1 Sandostatin® LAR Depot is a registered trademark of Novartis AG.

IR ContactsUnited StatesRan Meir(215) 591-8912
  Sanjeev Sharma(973) 658 2700
    
PR ContactsUnited StatesKelley Dougherty(973) 658-0237
  Yonatan Beker(973) 264 7378
 IsraelEden Klein972 (3) 906-2645


Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

THỦ THUẬT HAY

Cách nâng cấp lên Windows 10 từ Windows 7 hoặc 8 (phần 1)

Cuối cùng, hãy chắc chắn rằng bạn có 1 đến 2 giờ rảnh để chạy cài đặt. Mặc dù bạn có thể bỏ đi những phần lớn của quy trình, bạn có thể mong đợi tất cả việc tải xuống và sao chép tệp phải mất ít nhất 60 phút và trong

Hướng dẫn đăng ký và sử dụng dịch vụ eBanking tại Ngân hàng Đông Á

Internet Banking Service hay còn gọi EBanking là dịch vụ ngân hàng trực tuyến vô cùng tiện lợi, có mặt ở hầu hết các ngân hàng tại Việt Nam trong đó có cả Ngân hàng Đông Á (DongA Bank).

Hướng dẫn tải về hình ảnh trên Zalo về máy tính, điện thoại

Zalo là một ứng dụng nhắn tin, gọi điện miễn phí bằng internet rất được ưa chuộng tại Việt Nam. Ứng dụng Zalo được phát triển như là một mạng xã hội gồm nhiều chức năng như chia sẻ trạng thái, hình ảnh thể hiện cảm xúc

Cách đổi tên bạn bè trên Zalo như thế nào?

Một thủ thuật mà khá nhiều người dùng Zalo thắc mắc đó là đổi tên bạn bè trên Zalo như thế nào?. Bởi lẽ nhiều người sẽ thấy trong danh bạ Zalo có tên người dùng mà bạn đã đặt trong danh bạ điện thoại, nhưng lại có

8 mẹo chụp ảnh 'siêu trăng'

Để ISO thấp, chụp tốc độ không quá hai giây và sử dụng các ống kính tiêu cự trên 200 mm là những yếu tố quan trọng trong chụp 'siêu trăng'.

ĐÁNH GIÁ NHANH

Đánh giá Gionee S6s: Phá đảo phân khúc dưới 3,5 triệu đồng

Đánh giá chi tiết những điểm đáng đồng tiền bát gạo trên Gionee S6s. Sau khi giảm giá chính hãng đến cả triệu đồng, S6s liệu còn đáng mua ở phân...

Đánh giá BlackBerry KEY2 LE: Đáp ứng trọn vẹn những mong muốn của người hâm mộ dâu đen

Key2 LE - phiên bản rút gọn của chiếc Key2 là một chiếc máy đặc biệt của BlackBerry tại thị trường Việt Nam. Hiếm khi thương hiệu đến từ Canada này lại tung ra một chiếc máy được cho là có “giá tốt” như vậy.

iPhone 13 Pro Max nếu dùng bộ sạc công suất lớn sẽ có thể sạc nhanh hơn

Tốc độ sạc của iPhone 13 Pro Max vừa được một kênh Yotube thử nghiệm qua đó phát hiện chi tiết gây bất ngờ khi có tốc độ nhanh hơn iPhone 12 ...